101 related articles for article (PubMed ID: 7844405)
1. Human immunodeficiency virus type 1-infected patients with no disease progression display high-avidity antibody production to autologous V3 sequences.
Broström C; Sönnerberg A; Sällberg M
J Infect Dis; 1995 Feb; 171(2):509-11. PubMed ID: 7844405
[No Abstract] [Full Text] [Related]
2. Pattern of antibody response against the V3 loop in children with vertically acquired immunodeficiency virus type 1 (HIV-1) infection.
De Rossi A; Zanotto C; Mammano F; Ometto L; Del Mistro A; Chieco-Bianchi L
AIDS Res Hum Retroviruses; 1993 Mar; 9(3):221-8. PubMed ID: 7682425
[TBL] [Abstract][Full Text] [Related]
3. Loss of antibody reactivity directed against the V3 domain of certain human immunodeficiency virus type 1 variants during disease progression.
Schreiber M; Wachsmuth C; Müller H; Hagen C; Schmitz H; van Lunzen J
J Gen Virol; 1996 Oct; 77 ( Pt 10)():2403-14. PubMed ID: 8887471
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape.
Arendrup M; Sönnerborg A; Svennerholm B; Akerblom L; Nielsen C; Clausen H; Olofsson S; Nielsen JO; Hansen JE
J Gen Virol; 1993 May; 74 ( Pt 5)():855-63. PubMed ID: 7684062
[TBL] [Abstract][Full Text] [Related]
5. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
[TBL] [Abstract][Full Text] [Related]
6. Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide.
Ota A; Tanaka-Taya K; Ueda S
Hybridoma; 1999 Apr; 18(2):149-57. PubMed ID: 10380014
[TBL] [Abstract][Full Text] [Related]
7. Reactivity of AIDS patient sera with a peptide derived from HIV type 1NY5 glycoprotein 120 V3 loop and consensus sequence of collagens.
Metlas R; Skerl V; Pongor S; Colombatti A; Veljković V
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1425-6. PubMed ID: 7888196
[No Abstract] [Full Text] [Related]
8. Serotyping HIV-1 with V3 peptides: detection of high avidity antibodies presenting clade-specific reactivity.
Casseb J; Katzenstein D; Winters M; Brigido LF; Duarte AJ; Hendry RM
Braz J Med Biol Res; 2002 Mar; 35(3):369-75. PubMed ID: 11887216
[TBL] [Abstract][Full Text] [Related]
9. A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades.
Gorny MK; Mascola JR; Israel ZR; VanCott TC; Williams C; Balfe P; Hioe C; Brodine S; Burda S; Zolla-Pazner S
AIDS Res Hum Retroviruses; 1998 Feb; 14(3):213-21. PubMed ID: 9491911
[TBL] [Abstract][Full Text] [Related]
10. Peptide serology for analysis of the inter- and intra-individual variation in the HIV-1 V3 domain.
Jansson M; Wahren B; Albert J; Scarlatti G; Franzén L; Kataaha PK; Katabira E; Mubiro F; Wigzell H; Rossi P
AIDS; 1994 Apr; 8(4):413-21. PubMed ID: 8011244
[TBL] [Abstract][Full Text] [Related]
11. Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera.
Lawoko AL; Johansson B; Hjalmarsson S; Christensson B; Ljungberg B; Al-Khalili L; Sjölund M; Pipkorn R; Fenyö EM; Blomberg J
J Med Virol; 1999 Oct; 59(2):169-79. PubMed ID: 10459152
[TBL] [Abstract][Full Text] [Related]
12. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection.
Turbica I; Simon F; Besnier JM; LeJeune B; Choutet P; Goudeau A; Barin F
J Med Virol; 1997 Jul; 52(3):309-15. PubMed ID: 9210041
[TBL] [Abstract][Full Text] [Related]
13. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
[TBL] [Abstract][Full Text] [Related]
14. Anti-P30-52 monoclonal antibody cross-reacted to Env V3 and inhibited the viral multiplication of HIV-1-infected MT-4 cells.
Ota A; Bautista AN; Yadav ML; Ueda S
Hybridoma; 1999 Apr; 18(2):139-47. PubMed ID: 10380013
[TBL] [Abstract][Full Text] [Related]
15. V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1.
Krachmarov CP; Kayman SC; Honnen WJ; Trochev O; Pinter A
AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1737-48. PubMed ID: 11788025
[TBL] [Abstract][Full Text] [Related]
16. Human immunodeficiency virus V3 peptide-reactive antibodies are present in normal HIV-negative sera.
Metlas R; Trajkovic D; Srdic T; Veljkovic V; Colombatti A
AIDS Res Hum Retroviruses; 1999 May; 15(7):671-7. PubMed ID: 10331446
[TBL] [Abstract][Full Text] [Related]
17. Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries.
Boots LJ; McKenna PM; Arnold BA; Keller PM; Gorny MK; Zolla-Pazner S; Robinson JE; Conley AJ
AIDS Res Hum Retroviruses; 1997 Dec; 13(18):1549-59. PubMed ID: 9430247
[TBL] [Abstract][Full Text] [Related]
18. The reactivities of HIV-1+ human sera with solid-phase V3 loop peptides can be poor predictors of their reactivities with V3 loops on native gp120 molecules.
Moore JP
AIDS Res Hum Retroviruses; 1993 Mar; 9(3):209-19. PubMed ID: 8471311
[TBL] [Abstract][Full Text] [Related]
19. Diversity of antibody binding to V3 peptides representing consensus sequences of HIV type 1 genotypes A to E: an approach for HIV type 1 serological subtyping.
Barin F; Lahbabi Y; Buzelay L; Lejeune B; Baillou-Beaufils A; Denis F; Mathiot C; M'Boup S; Vithayasai V; Dietrich U; Goudeau A
AIDS Res Hum Retroviruses; 1996 Sep; 12(13):1279-89. PubMed ID: 8870850
[TBL] [Abstract][Full Text] [Related]
20. Effect of anti-V3 antibodies on cell-free and cell-to-cell human immunodeficiency virus transmission.
Pantaleo G; Demarest JF; Vaccarezza M; Graziosi C; Bansal GP; Koenig S; Fauci AS
Eur J Immunol; 1995 Jan; 25(1):226-31. PubMed ID: 7843235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
